Bridging Gaps for Radioligand Therapy: Policy Priorities for Scaled Implementation

BackgroundRadioligand therapy (RLT) represents a transformative advancement in precision cancer treatment, improving outcomes of patients with advanced cancers.Despite growing clinical evidence demonstrating favorable benefit-risk profiles of RLTs, outdated regulatory frameworks continue to restrict patient access.This report aims to bridge the critical gap between scientific evidence and policy implementation by providing actionable recommendations that enable healthcare systems to optimize RLT delivery while maintaining safety standards. MethodologyThis broad analysis examined regulatory frameworks, clinical guidelines, and real-world implementation data across multiple healthcare systems, focusing on countries with stringent hospitalization requirements (e.g., Germany, Japan) and those applying evidence-based protocols (e.g., United Kingdom, United States).Evidence was assessed using the RLT Readiness Assessment Framework (a) across seven focus areas to identify policy gaps and implementation challenges. Key FindingsCurrent policies perpetuate historical precedents rather than reflecting contemporary evidence.Hospitalization requirements vary widely across countries, from 1-4 hours in the United States to 72-96 hours in Japan, driven by policy choices rather than medical necessity.Systemic policy gaps were identified across seven domains: (1) fragmented governance creating conflicting safety standards; (2) infrastructure concentrated in urban centers and without systematic planning to meet future demands; (3) radiation safety protocols inconsistent with current risk-benefit profiles of RLTs; (4) workforce shortages; (5) health technology assessment and payment systems inadequate to capture the full value of RLT, thereby penalizing efficient care delivery; (6) absence of real-world evidence collection mechanisms; and (7) limited stakeholder awareness of RLT safety and efficacy.The economic impact is substantial: evidence-based 24-hour discharge protocols could increase patient throughput by 67% compared to current 48-72-hour requirements, expanding access while maintaining safety.International best practices from Belgium, Italy, Switzerland, and the United Kingdom demonstrate that evidence-based reform is both feasible and beneficial. InterpretationCoordinated reforms in post-treatment discharge criteria, payment models, and RLT-specific assessment frameworks can simultaneously improve patient outcomes, enhance system efficiency, and expand equitable access to breakthrough treatments.